All In Biotech

BLA 103964 · Pharmaand Gmbh

Pegasys

Peginterferon Alfa-2a · Subcutaneous · Interferon alpha

Novel

Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Oct 16, 2002

Approved uses

10

Original approval plus efficacy supplements

Registered trials

517

140 Phase 3, 5 recruiting

FAERS reports

53,802

22,928 serious, 1,801 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS DISORDERS WARNING: RISK OF SERIOUS DISORDERS See full prescribing information for complete boxed warning. Risk of Serious Disorders May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders ( 5 ) Risk of Serious Disorders Alpha interferons, including PEGASYS (peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy [see Warnings...

What it is approved for

From the label in effect Oct 16, 2026.

PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT) 1.1 Chronic Hepatitis C (CHC) Adult Patients: PEGASYS, as part of a combination regimen with other hepatitis C virus (HCV) antiviral drugs, is indicated for the treatment of adults with CHC and compensated liver disease. For information about the safe and effective use of other HCV antiviral drugs to be used in combination with PEGASYS, refer to their prescribing information. PEGASYS monotherapy is only indicated for the treatment of patients with CHC and compensated liver disease if there are contraindications or significant intolerance to other HCV antiviral drugs. Pediatric Patients: PEGASYS in combination with ribavirin is indicated for the treatment of pediatric patients 5 years of age and older with CHC and compensated liver disease. Limitations of Use : PEGASYS alone or in combination with ribavirin without additional HCV antiviral drugs is not recommended...

Mechanism: Pegylated recombinant human interferon alfa-2a is an inducer of the innate antiviral immune response [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PEGASYS · PEGINTERFERON ALFA-2A 180U/5ML · SYRINGE, · Prescription
  • PEGASYS · PEGINTERFERON ALFA-2A 180UG/VIAL · VIAL, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Peginterferon Alfa-2a" as an intervention, any sponsor and status, largest first.

All 517 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue9,266
  • nausea7,167
  • anaemia6,637
  • rash4,877
  • headache4,456
  • white blood cell count decreased4,232
  • pruritus4,227
  • pyrexia3,478
  • diarrhoea3,388
  • vomiting3,338
  • asthenia3,152
  • insomnia3,079

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004473
20051,118
2006661
2007655
2008786
2009971
20101,192
20111,492
201213,773
20138,523
20143,095
201517,300
2016869
2017546
2018386
2019326
2020349
2021249
2022301
2023194
2024182
2025213
2026144

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Resolved · updated Aug 27, 2026

    Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4).

  • Resolved · updated Aug 27, 2026

    Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: PEGasys (PEGinterferon Alfa-2a)

2024 spending

$31.0M

Beneficiaries

1,095

8,086 claims

Per beneficiary

$28,327

$1,473.91 per unit

View as table
YearSpending
2020$0
2021$0
2022$9,274,874
2023$25,889,832
2024$31,018,422

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 269 on PubMed

Sponsor: Pharmaand Gmbh

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.